<DOC>
	<DOCNO>NCT02488967</DOCNO>
	<brief_summary>This randomized phase III trial study well doxorubicin hydrochloride cyclophosphamide follow paclitaxel without carboplatin work treat patient triple-negative breast cancer . Drugs use chemotherapy , doxorubicin hydrochloride , cyclophosphamide , paclitaxel , carboplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . It yet know whether doxorubicin hydrochloride cyclophosphamide effective follow paclitaxel alone paclitaxel carboplatin treat triple-negative breast cancer .</brief_summary>
	<brief_title>Doxorubicin Hydrochloride Cyclophosphamide Followed Paclitaxel With Without Carboplatin Treating Patients With Triple-Negative Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether addition carboplatin adjuvant chemotherapy regimen doxorubicin ( doxorubicin hydrochloride ) /cyclophosphamide follow paclitaxel improve invasive disease-free survival ( IDFS ) compare doxorubicin/cyclophosphamide follow paclitaxel administered patient operable node-positive high-risk node-negative triple-negative breast cancer . SECONDARY OBJECTIVES : I . To determine whether addition carboplatin adjuvant chemotherapy regimen doxorubicin/cyclophosphamide follow paclitaxel improve overall survival ( OS ) compare doxorubicin/cyclophosphamide follow paclitaxel administered patient operable node-positive high-risk node-negative triple-negative breast cancer . II . To determine whether addition carboplatin adjuvant chemotherapy regimen doxorubicin/cyclophosphamide follow paclitaxel improve breast cancer-free survival ( BCFS ) compare doxorubicin/cyclophosphamide follow paclitaxel administered patient operable node-positive high-risk node-negative triple-negative breast cancer . III . To determine whether addition carboplatin adjuvant chemotherapy regimen doxorubicin/cyclophosphamide follow paclitaxel improve recurrence-free interval ( RFI ) compare doxorubicin/cyclophosphamide follow paclitaxel administered patient operable node-positive high-risk node-negative triple-negative breast cancer . IV . To determine whether addition carboplatin adjuvant chemotherapy regimen doxorubicin/cyclophosphamide follow paclitaxel improve distant recurrence-free interval ( DRFI ) compare doxorubicin/cyclophosphamide follow paclitaxel administered patient operable node-positive high-risk node-negative triple-negative breast cancer . V. To determine toxicity doxorubicin/cyclophosphamide follow paclitaxel administer concurrently carboplatin compare toxicity doxorubicin/cyclophosphamide follow paclitaxel alone . VI . To determine germline breast cancer ( BRCA ) status associate benefit IDFS OS addition carboplatin adjuvant chemotherapy regimen doxorubicin/cyclophosphamide follow paclitaxel patient operable node-positive high-risk node-negative triple-negative breast cancer . VII . To determine addition carboplatin improve RFI among homologous recombination ( HR ) deficient patient determine homologous recombination deficiency ( HRD ) score . VIII . To determine whether efficacy carboplatin RFI HR-deficient patient differs patient HR-deficient . IX . To collect tissue blood sample several occasion future biomarkers development predict risk breast cancer recurrence patient operable node-positive high-risk node-negative triple-negative breast cancer treat doxorubicin/cyclophosphamide follow paclitaxel without carboplatin predict benefit addition carboplatin among patient . OUTLINE : Patients randomize 1 2 treatment arm . ARM I ( DOXORUBICIN HYDROCHLORIDE [ A ] CYCLOPHOSPHAMIDE [ C ] -- &gt; WEEKLY PACLITAXEL [ WP ] ) : Patients receive doxorubicin hydrochloride intravenously ( IV ) 15 minute cyclophosphamide IV 30 minute day 1 . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . Patients receive paclitaxel IV 60 minute day 1 . Treatment repeat weekly 12 course absence disease progression unacceptable toxicity . ARM II ( AC -- &gt; WP + CARBOPLATIN ) : Patients receive doxorubicin hydrochloride cyclophosphamide Arm I . Patients receive paclitaxel IV 60 minute day 1 , 8 , 15 carboplatin IV 30-60 minute day 1 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 5 year every 12 month 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>The patient must sign dated institutional review board ( IRB ) approve consent form conform federal institutional guideline Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 The tumor must unilateral invasive adenocarcinoma breast histologic examination All follow stag criterion ( accord 7th edition American Joint Committee Cancer [ AJCC ] Cancer Staging Manual ) must meet : By pathologic evaluation , primary tumor must pT13 By pathologic evaluation , ipsilateral node must pN0 , pN1 ( pN1mi , pN1a , pN1b , pN1c ) , pN2a , pN2b , pN3a , pN3b If pN0 , tumor must &gt; 3.0 cm The tumor must determine human epidermal growth factor receptor 2 ( HER2 ) negative follow : Immunohistochemistry ( IHC ) 01+ ; IHC 2+ situ hybridization ( ISH ) nonamplified ratio HER2 centromere enumerator probe 17 ( CEP17 ) &lt; 2.0 , report , average HER2 gene copy number &lt; 4 signals/cells ; ISH nonamplified ratio HER2 CEP17 &lt; 2.0 , report , average HER2 gene copy number &lt; 4 signals/cells The tumor must determine estrogen receptor ( ER ) progesterone receptor ( PgR ) negative assess current American Society Clinical Oncology ( ASCO ) /College American Pathologists ( CAP ) guideline ; patient &lt; 1 % ER PgR stain IHC consider negative The patient must undergo either mastectomy ( total , skinsparing , nipplesparing ) lumpectomy For patient undergo lumpectomy , margin resect specimen must histologically free invasive tumor ductal carcinoma situ ( DCIS ) determine local pathologist ; pathologic examination demonstrate tumor line resection , additional excision may perform obtain clear margin ; tumor still present resect margin reexcision ( ) , patient must undergo mastectomy eligible ; ( patient margin positive lobular carcinoma situ [ LCIS ] eligible without additional resection ) For patient undergo mastectomy , margin must free residual gross tumor ; ( patient microscopic positive margin eligible long postmastectomy radiation therapy [ RT ] chest wall administer ) The patient must complete one procedure evaluation pathologic nodal status list . Sentinel lymphadenectomy alone : If pathologic nodal stag base sentinel lymphadenectomy pN0 pN1b ; If pathologic nodal stag base sentinel lymphadenectomy pN1mi pN1a patient undergone breast conserving surgery ( plan breast radiotherapy ) , primary tumor must T1 T2 pathologic evaluation nodal involvement must limit 1 2 positive node Sentinel lymphadenectomy follow removal additional nonsentinel lymph node sentinel node ( SN ) positive ; Axillary lymphadenectomy without SN isolation procedure The interval last surgery breast cancer ( include reexcision margin ) randomization must 60 day Absolute neutrophil count ( ANC ) must &gt; = 1200/mm^3 Platelet count must &gt; = 100,000/mm^3 Hemoglobin must &gt; = 10 g/dL Total bilirubin must = &lt; upper limit normal ( ULN ) laboratory ( lab ) unless patient bilirubin elevation &gt; ULN 1.5 x ULN due Gilbert 's disease similar syndrome involve slow conjugation bilirubin Alkaline phosphatase must = &lt; 2.5 x ULN lab Aspartate aminotransferase ( AST ) must = &lt; 1.5 x ULN lab Note : If alanine aminotransferase ( ALT ) perform instead AST ( per institution 's standard practice ) , ALT value must = &lt; 1.5 x ULN ; perform , AST must = &lt; 1.5 x ULN Patients AST alkaline phosphatase &gt; ULN eligible inclusion study liver image ( compute tomography [ CT ] , magnetic resonance image [ MRI ] , positron emission tomography [ PET ] CT , PET scan ) perform within 90 day prior randomization demonstrate metastatic disease requirement meet Patients alkaline phosphatase &gt; ULN = &lt; 2.5 x ULN unexplained bone pain eligible inclusion study bone scan , PETCT scan , PET scan perform within 90 day prior randomization demonstrate metastatic disease Adequate renal function determine within 6 week prior randomization define recent serum creatinine = &lt; ULN measure calculated creatinine clearance &gt; 60 mL/min Left ventricular ejection fraction ( LVEF ) assessment must perform within 90 day prior randomization ; ( LVEF assessment perform 2dimensional [ D ] echocardiogram prefer ; however , multi gated acquisition [ MUGA ] scan may substitute base institutional preference ; ) LVEF must &gt; = 50 % regardless cardiac image facility 's low limit normal T4 tumor include inflammatory breast cancer Definitive clinical radiologic evidence metastatic disease ; require imaging study must perform within 90 day prior randomization Synchronous previous contralateral invasive breast cancer ; ( patient synchronous and/or previous contralateral DCIS LCIS eligible ) Any previous history ipsilateral invasive breast cancer ipsilateral DCIS ; ( patient synchronous previous ipsilateral LCIS eligible ) History nonbreast malignancy ( except situ cancer treat local excision basal cell squamous cell carcinoma skin ) within 5 year prior randomization Previous therapy anthracyclines taxanes malignancy Chemotherapy administer currently diagnose breast cancer prior randomization Any continue use sex hormonal therapy , e.g. , birth control pill , ovarian hormone replacement therapy ; patient eligible medication discontinue prior randomization Cardiac disease ( history and/or active disease ) would preclude use drug include treatment regimen ; include confine : Active cardiac disease Angina pectoris require current use antianginal medication ; Ventricular arrhythmias except benign premature ventricular contraction ; Supraventricular nodal arrhythmia require pacemaker control medication ; Conduction abnormality require pacemaker ; Valvular disease document compromise cardiac function ; Symptomatic pericarditis History cardiac disease Myocardial infarction document elevated cardiac enzyme persistent regional wall abnormality assessment leave ventricle ( LV ) function ; History document congestive heart failure ( CHF ) ; Documented cardiomyopathy Uncontrolled hypertension define sustain systolic blood pressure ( BP ) &gt; 150 mmHg diastolic BP &gt; 90 mmHg ; ( patient initial BP elevation eligible initiation adjustment BP medication lower pressure meet entry criterion ) Active hepatitis B hepatitis C abnormal liver function test Patients know human immunodeficiency virus ( HIV ) positive baseline cluster differentiation ( CD ) 4 count &lt; 250 cells/mm^3 history acquire immune deficiency syndrome ( AIDS ) indicator condition Intrinsic lung disease result dyspnea History hospitalization past 12 month diabetic ketoacidosis ( DKA ) hyperosmolar hyperglycemic nonketotic syndrome ( HHNS ) Active infection chronic infection require chronic suppressive antibiotic Nervous system disorder ( paresthesia , peripheral motor neuropathy , peripheral sensory neuropathy ) &gt; = grade 2 , per Common Terminology Criteria Adverse Events ( CTCAE ) version ( v ) 4.0 Conditions would prohibit administration corticosteroid Chronic daily treatment corticosteroid dose &gt; = 10 mg/day methylprednisolone equivalent ( exclude inhale steroid ) Known hypersensitivity study drug excipients , e.g. , polysorbate 80 Cremophor® EL Other nonmalignant systemic disease would preclude patient receive study treatment would prevent require followup Psychiatric addictive disorder condition , opinion investigator , would preclude patient meeting study requirement Pregnancy lactation time study entry ; ( note : pregnancy test accord institutional standard woman childbearing potential must perform within 2 week prior randomization ) Use investigational product within 4 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>